John Ng (L) and Wilson Cheung (Tessa)

With deep ties to Bay­lor and fresh sup­port from Po­laris, Sin­ga­pore's Tes­sa rais­es $126M for piv­otal CAR study

Tes­sa Ther­a­peu­tics in Sin­ga­pore has been through mul­ti­ple rais­es over the last decade for its cell ther­a­py R&D work. But with US-based VC Po­laris step­ping in to lead the new $126 mil­lion round as it sits on the thresh­old of a piv­otal ex­pe­di­tion in the clin­ic fo­cused on the US and Eu­rope, they’re call­ing this new one to­day a Se­ries A.

Go fig­ure.

That fresh raise comes on top of the more than $200 mil­lion al­ready gar­nered for its work, in­ter­im CEO John Ng tells me. Temasek, the $283 bil­lion sov­er­eign wealth fund in Sin­ga­pore that’s played a ma­jor role in build­ing the coun­try’s tech in­dus­try, has been a key play­er here. ED­BI, He­li­co­nia Cap­i­tal and Her­i­tas Cap­i­tal al­so fig­ure in as ex­ist­ing in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.